Trend Spotting: The Top 9 Rise & Falls We See in the Year Ahead

the problem of nuclear waste, and other breakthrough companies that will soon emerge from stealth with high-power energy conversion for electric vehicles and industrial motors. Just like the PC business in the 1980s, picking brands will be tough, but betting on the digital guts inside may make fortunes.

5. The Rise of Surprise

The most exciting things always come from unexpected upside surprises. Watch for not-widely followed areas of science and technology. Metamaterials, graphene, battery breakthroughs, solid-state lighting, augmented reality, computational photography, better energy storage and regenerative medicine are all hot areas that Lux and other VCs are on the hunt for.

6. The Fall of Super-Angels

When barriers to competition are low, expect lots of it. Hundreds of companies are getting funded by so called super angels or micro-VCs, but valuations are in the nosebleed sections. As momentum in sectors like social-networking slows (or gets saturated), some angels’ staying power could wilt as follow-on financing face tougher terms from larger VCs.

7. The Fall of Personal Privacy (& The Rise of Good Behavior?)

Regardless of what privacy advocates say: between diplomacy hackers like WikiLeaks, industrial hackers like the Stuxnet virus, geo-tagging, real-time data, status updates, tweets, check-ins, and phone cams in the hands of everyone-the facts is this: personal privacy has irreparably changed. Tech guru Kevin Kelly made a provocative statement: nobody really knows what any technology will be good for: the real question is what happens when everyone has one? Now compare modern technology as an unblinking eye with Southern gun culture. Some believe Southern gentility arose from a gun culture, where politeness was a survival tactic. If people assume they’re being watched all the time, what affect might it have on ethics and behavior?

8. The Rise of Robotics

From UAVs (unmanned aerial vehicles), and military drones to autonomous systems in hospitals, factories, and shipping centers: expect robots to do the mundane, the menacing, and the miraculous.

9. The Rise of Risk

The world is more connected, less predictable and more volatile than ever before. Models widely taught in universities that assumed linear cause-and-effect, or even bell-shaped distributions in markets, are proving to contribute to more risky systems and bad decision-making. As John Maynard Keynes said, it’s better to be roughly right than precisely wrong. Low probability, high consequence events, so-called Black Swans, are on the rise with greater frequency and less predictability. Whether it’s financial crises, weather systems, or geopolitical instability-the best way to deal with risk is to know more things can happen than will and you should expect the unexpected.

[Editor’s Note: This is part of a series of posts from Xconomists and other technology and life sciences leaders from around the U.S. who are weighing in with the top surprises they’ve seen in their respective fields in the past year, or the major things to watch for in 2011.]

Author: Larry Bock

In Memoriam: Our friend and Xconomist Larry Bock passed away on July 6, 2016. We at Xconomy are deeply saddened by his loss. Larry Bock is the founder and organizer of the USA Science & Engineering Festival, and a former founder of the San Diego Science Festival. Mr. Bock is a Special Limited Partner to Lux Capital, a $100M nanotechnology-focused venture capital fund. He is a member of the Board of Directors of FEI Corporation (NASDAQ: FEIC), the leading supplier of tools for nanotechnology research. He is a General Partner of CW Ventures, a $100M life sciences venture capital fund. Mr. Bock was the founder and former executive chairman and initial CEO of Nanosys and the founder and initial CEO of Neurocrine Biosciences (NASDAQ: NBIX), Pharmacopeia (NASDAQ: PCOP), GenPharm International, which was acquired by Medarex for $100 million; Caliper Technologies (NASDAQ: CALP); Illumina Technologies (NASDAQ: ILMN), among numerous other firms. He was also a seed or early-stage investor in variety of firms, including Acceleron Pharma, Aurora Biosciences, Biosym Technologies, ekoVenture. Gen-Probe, Gensia Pharmaceuticals, Genocea Biosciences, IDEC Pharmaceuticals Magen Biosciences, Oclassen Pharmaceuticals Plexikon Pharmaceuticals, Poland Partners, Sequana Therapeutics, Sapphire Energy, Siluria, Sirtris Pharmaceuticals, Software Transformation, and Viagene. Mr. Bock started his career as a researcher in the early days at Genentech, the field of infectious diseases, where he was on the team that received the AAAS Newcomb Cleveland Prize for demonstrating the world’s first recombinant DNA vaccine. He was a Venture Capital Associate with Fairfield Ventures (now Oxford Bioventures). Larry and his wife, Diane, established the Larry and Diane Bock Chair in Nanotechnology at the University of California, Berkeley. They also founded Community Cousins, a non-profit foundation focused on breaking down racial barriers, that was selected by former Vice President Al Gore as one of 10 outstanding grass root efforts nationally. Larry is organizing the San Diego Science Festival with BioBridge of UCSD. He works extensively with the Sudanese and Burmese refugee’s networks in San Diego and is a tutor in math and sciences for Sudanese refugee children in St. Lukes Sudanese Refugee Network and a Mentor for Burmese refugee families through Jewish Family Services. Larry received his B.A. in Biochemistry (summa cum laude) from Bowdoin College and his M.B.A. from the Anderson School at UCLA.